These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22203487)

  • 1. Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy.
    Vlachaki E; Kalogeridis A; Neokleous N; Perifanis V; Klonizakis F; Ioannidou E; Klonizakis I
    Mol Biol Rep; 2012 May; 39(5):6101-5. PubMed ID: 22203487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of JAK2V617F Mutation Prevalence in Patients with Beta Thalassemia Major.
    Tahannejad Asadi Z; Yarahmadi R; Saki N; Jalali MT; Amin Asnafi A; Tangestani R
    Lab Med; 2020 Mar; 51(2):176-180. PubMed ID: 31495895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.
    Ayad MW; Nafea D
    Genet Test Mol Biomarkers; 2011; 15(1-2):17-21. PubMed ID: 21034166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK and MPL mutations in myeloid malignancies.
    Tefferi A
    Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK-2 mutations and their relevance to myeloproliferative disease.
    Levine RL; Gilliland DG
    Curr Opin Hematol; 2007 Jan; 14(1):43-7. PubMed ID: 17133099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.
    Casu C; Oikonomidou PR; Chen H; Nandi V; Ginzburg Y; Prasad P; Fleming RE; Shah YM; Valore EV; Nemeth E; Ganz T; MacDonald B; Rivella S
    Blood; 2016 Jul; 128(2):265-76. PubMed ID: 27154187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloproliferative neoplasms and JAK2 mutations.
    Almedal H; Vorland M; Aarsand AK; Grønningsæter IS; Bruserud Ø; Reikvam H
    Tidsskr Nor Laegeforen; 2016 Dec; 136(22):1889-1894. PubMed ID: 27929554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
    Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etiology and incidence of thrombotic and hemorrhagic disorders in Thai patients with extreme thrombocytosis.
    Chuncharunee S; Archararit N; Ungkanont A; Jootar S; Angchaisuksiri P; Bunyaratavej A; Rojanasthein S; Atichartakarn V
    J Med Assoc Thai; 2000 Mar; 83 Suppl 1():S95-100. PubMed ID: 10865414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
    James C
    Hematology Am Soc Hematol Educ Program; 2008; ():69-75. PubMed ID: 19074061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
    Ebid GT; Ghareeb M; Salaheldin O; Kamel MM
    Int J Clin Exp Pathol; 2015; 8(9):11555-9. PubMed ID: 26617890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause.
    Strobbe L; Lestrade P; Hermans MH; Fijnheer R
    Ann Hematol; 2007 Nov; 86(11):801-3. PubMed ID: 17703302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of mutations in myeloproliferative neoplasms.
    Levine RL
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):489-94. PubMed ID: 19959098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
    Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New advances in the pathogenesis and therapy of essential thrombocythemia.
    Levine RL; Heaney M
    Hematology Am Soc Hematol Educ Program; 2008; ():76-82. PubMed ID: 19074062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
    Tefferi A
    Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
    Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
    Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.